-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Johnson & Johnson announced on March 13 that the World Health Organization (WHO) has approved the emergency use list (EUL) application for a single-dose new coronary pneumonia vaccine developed by Johnson & Johnson's Janssen Pharmaceutical Company (hereinafter referred to as "Janssen").
Data from the Phase 3 ENSEMBLE study showed that Johnson & Johnson's new coronary pneumonia vaccine was well tolerated, and the incidence of symptomatic new coronary pneumonia after vaccination was 67% lower than that of subjects in the placebo group.
The EUL procedure simplifies the process by which governments and United Nations procurement agencies evaluate new or unapproved products for use during public health emergencies.